Capital World Investors’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.63B Buy
30,075,134
+1,810,554
+6% +$341M 0.67% 38
2026
Q1
$5.52B Buy
28,264,580
+27,807,540
+6,084% +$5.36B 0.75% 28
2025
Q4
$84.1M Sell
457,040
-89,770
-16% -$15.7M 0.01% 371
2025
Q3
$83.5M Buy
546,810
+470,031
+612% +$71.1M 0.01% 359
2025
Q2
$10.7M Buy
76,779
+2,119
+3% +$297K ﹤0.01% 499
2025
Q1
$11M Buy
74,660
+3,145
+4% +$455K ﹤0.01% 484
2024
Q4
$9.38M Sell
71,515
-3,055,826
-98% -$428M ﹤0.01% 480
2024
Q3
$487M Buy
3,127,341
+1,171
+0% +$189K 0.08% 195
2024
Q2
$488M Sell
3,126,170
-1,556,668
-33% -$234M 0.08% 184
2024
Q1
$635M Buy
4,682,838
+14,748
+0.3% +$1.95M 0.11% 175
2023
Q4
$629M Buy
4,668,090
+209
+0% +$27.2K 0.11% 171
2023
Q3
$632M Buy
4,667,881
+94,879
+2% +$13M 0.13% 161
2023
Q2
$654M Buy
4,573,002
+404,889
+10% +$59.6M 0.13% 167
2023
Q1
$579M Buy
4,168,113
+551,152
+15% +$74.2M 0.12% 175
2022
Q4
$490M Buy
3,616,961
+1,898,534
+110% +$238M 0.1% 182
2022
Q3
$188M Buy
1,718,427
+600,091
+54% +$76.1M 0.04% 274
2022
Q2
$148M Sell
1,118,336
-1,474,906
-57% -$194M 0.03% 299
2022
Q1
$344M Sell
2,593,242
-4,651
-0.2% -$558K 0.06% 241
2021
Q4
$303M Buy
2,597,893
+8,310
+0.3% +$978K 0.05% 273
2021
Q3
$311M Buy
2,589,583
+107,212
+4% +$12.5M 0.05% 260
2021
Q2
$297M Buy
2,482,371
+158,972
+7% +$17.4M 0.05% 265
2021
Q1
$231M Buy
2,323,399
+8,525
+0.4% +$857K 0.04% 281
2020
Q4
$231M Sell
2,314,874
-443,916
-16% -$47M 0.04% 268
2020
Q3
$302M Buy
2,758,790
+3,836
+0.1% +$427K 0.07% 235
2020
Q2
$291M Buy
2,754,954
+13,336
+0.5% +$1.38M 0.07% 217
2020
Q1
$245M Buy
2,741,618
+771,833
+39% +$72.7M 0.07% 211
2019
Q4
$196M Sell
1,969,785
-2,937,825
-60% -$277M 0.04% 259
2019
Q3
$437M Buy
4,907,610
+272,480
+6% +$23.6M 0.11% 178
2019
Q2
$383M Buy
4,635,130
+397,619
+9% +$31.2M 0.09% 187
2019
Q1
$343M Buy
4,237,511
+1,237,499
+41% +$97.5M 0.08% 196
2018
Q4
$228M Sell
3,000,012
-503,264
-14% -$39.3M 0.06% 217
2018
Q3
$277M Buy
3,503,276
+4
+0% +$303 0.07% 215
2018
Q2
$246M Hold
3,503,272
0.05% 225
2018
Q1
$245M Buy
3,503,272
+1,263,980
+56% +$87.6M 0.06% 225
2017
Q4
$155M Buy
2,239,292
+2
+0% +$135 0.03% 258
2017
Q3
$152M Buy
2,239,290
+2,009,287
+874% +$127M 0.03% 255
2017
Q2
$15.7M Buy
230,003
+3
+0% +$196 ﹤0.01% 440
2017
Q1
$14.3M Hold
230,000
﹤0.01% 441
2016
Q4
$12.6M Hold
230,000
﹤0.01% 437
2016
Q3
$15.1M Hold
230,000
﹤0.01% 421
2016
Q2
$13.9M Sell
230,000
-1,145,000
-83% -$66.5M ﹤0.01% 420
2016
Q1
$77.4M Buy
1,375,000
+445,000
+48% +$26.7M 0.02% 300
2015
Q4
$63.1M Buy
930,000
+700,000
+304% +$45.9M 0.02% 321
2015
Q3
$14.6M Hold
230,000
﹤0.01% 451
2015
Q2
$14.7M Hold
230,000
﹤0.01% 470
2015
Q1
$15.7M Hold
230,000
﹤0.01% 461
2014
Q4
$16.2M Sell
230,000
-80,000
-26% -$5.73M ﹤0.01% 455
2014
Q3
$22.1M Hold
310,000
0.01% 423
2014
Q2
$23M Sell
310,000
-700,000
-69% -$50.6M 0.01% 416
2014
Q1
$65.5M Sell
1,010,000
-660,000
-40% -$42.6M 0.02% 331
2013
Q4
$99.1M Hold
1,670,000
0.03% 297
2013
Q3
$86.7M Hold
1,670,000
0.03% 305
2013
Q2
$79M Buy
+1,670,000
New +$85M 0.03% 306

Other funds holding AZN

Capital World Investors's AZN Position: Q2 2026 in Review

Capital World Investors increased its AstraZeneca (AZN) stake by 6.4% in Q2 2026, buying an estimated $341M and bringing the position to 30,075,134 shares worth $5.63B. The position accounts for 0.67% of the portfolio, ranked #38.

Capital World Investors first reported a position in AZN in Q2 2013 and has held it in 53 quarters since. 1,259 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Capital World Investors held 30,075,134 shares of AstraZeneca worth $5.63B as of Q2 2026.
  • Capital World Investors bought 1,810,554 AstraZeneca shares in Q2 2026, an estimated $341M.
  • AstraZeneca made up 0.67% of Capital World Investors's portfolio in Q2 2026, its #38 holding.
  • Capital World Investors first reported a position in AstraZeneca in Q2 2013 and has held it in 53 quarters since.
  • 1,259 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Capital World Investors's 13F filing for Q2 2026, filed 12 Aug 2026.